Agios Pharmaceuticals Inc (AGIO) posted record Q3 2026 revenue of $55.4 million, cut R&D headcount by over 35%, and is launch-ready for sickle cell ahead of a February 2027 PDUFA date.
Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.
Agios Pharmaceuticals reported that the FDA has extended the PDUFA goal date for its Priority Review sNDA for mitapivat in sickle cell disease to February 1, 2027, after the agency classified new safety data and REMS related information as a major amendment. The firm is leaning on extensive RISE UP and REIGNITE trial data and ongoing labeling talks to keep mitapivat’s sickle cell opportunity on track, despite a longer review clock and added regulatory work on potential REMS requirements. We...
Agios Pharmaceuticals stock fell >15% after the FDA extended the mitapivat sNDA PDUFA date for sickle cell disease to February 2027. I rate AGIO stock as Buy. Read my update.
Agios Pharmaceuticals (AGIO) stock fell after the FDA delayed the review of the firm's application for a label expansion of its lead product, Pyrukynd. Read more here.
Agios Pharmaceuticals is pursuing US FDA accelerated approval for mitapivat in sickle cell disease after Priority Review of Phase 3 RISE UP data showing significant hemoglobin responses in patients aged 16 and older. The mixed RISE UP outcome, with strong hemoglobin results but no statistically significant reduction in pain crises, highlights both the clinical opportunity and the trial design risk Agios must manage as it builds a rare disease franchise around mitapivat. We will examine how...
Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.